medigraphic.com
Academia Mexicana de Neurología, A.C.

2018, Número 1

<< Anterior Siguiente >>

Rev Mex Neuroci 2018; 19 (1)


Corea de sydenham: revisión práctica de la literatura actual

Vásquez-Builes S, Correa-Roldan MC, Rojas-Gallego IC, Tieck MP, Díaz-Silva GA

Idioma: Español
Referencias bibliográficas: 67
Paginas: 56-67
Archivo PDF: 289.14 Kb.


RESUMEN

Los trastornos del movimiento inmuno-mediados nos han acompañado a lo largo de la historia. La corea de Sydenham, el más frecuente de estos trastornos, fue descrito en el siglo XVII y aun es reconocida como la causa más común de corea adquirida durante la infancia. A pesar de su clara relación con la fiebre reumática, la patogénesis de la corea de Sydenham no ha sido completamente dilucidada. La similitud entre determinantes antigénicos de proteínas del estreptococo beta hemolítico del grupo A y proteínas neuronales ubicadas en los núcleos basales del huésped podrían llevar a una reacción inmune cruzada y explicar las anormalidades funcionales y parte de las manifestaciones clínicas, motoras y cognitivas, descritas en este trastorno. Las manifestaciones clínicas de la corea de Sydenham son diversas por lo cual el diagnóstico y el tratamiento a menudo requieren enfoques multimodales.
En la presente revisión se realiza una descripción práctica y detallada de la literatura actual sobre la corea de Sydenham enfatizando en aspectos clínicos, fisiopatológicos y terapéuticos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Díaz-Grez F, Lay-Son L, Del Barrio-Guerrero E, Vidal-González P. Corea de Sydenham. Análisis clínico de 55 pacientes con seguimiento prolongado. Rev Neurol. 2004;39:810–5.

  2. Mestre TA. Chorea. Continuum. (Minneap Minn) 2016;22:1186-207.

  3. Lanska DJ. The history of movement disorders. Handb Clin Neurol. 2010;95:501-46.

  4. Vale TC, Cardoso. Chorea: A journey through history. Tremor Other Hyperkinet Mov. 2015;5:5.

  5. Taranta A, Stollerman GH. The relationship of Sydenham’s chorea to infection with group A streptococci. Am J Med. 1956;20:170-5.

  6. Jones TD. Diagnosis of rheumatic fever. JAMA. 1944;126:481-4.

  7. Jones criteria (revised) for guidance in the diagnosis of rheumatic fever. Circulation. 1965;32:664-8.

  8. Singer HS. Autoantibody-associated movement disorders in children: proven and proposed. Semin Pediatr Neurol. 2017;24:168-79.

  9. Dale RC, Brilot F. Autoimmune basal ganglia disorders. J Child Neurol. 2012;27:1470-81.

  10. Mohammad SS, Ramanathan S, Brilot F, Dale RC. Autoantibody-associated movement disorders. Neuropediatrics. 2013;44:336-45.

  11. Cardoso F. Autoimmune choreas. J Neurol Neurosurg Psychiatry. 2017;88:412-7

  12. Oosterveer DM, Overweg-Plandsoen WC, Roos RA. Sydenham’s chorea: a practical overview of the current literature. Pediatr Neurol. 2010;43:1-6.

  13. Carapetis JR, Currie BJ. Rheumatic chorea in northern Australia: a clinical and epidemiological study. Arch Dis Child. 1999;80:353-8.

  14. Cardoso F. Sydenham’s chorea. Handb Clin Neurol. 2011;100:221-9.

  15. Dale RC. Immune-mediated extrapyramidal movement disorders, including Sydenham chorea. Handb Clin Neurol. 2013;112:1235-41.

  16. Kotby AA, El Badawy N, El Sokkary S, Moawad H, El Shawarby M. Antineuronal antibodies in rheumatic chorea. Clin Diagn Lab Immunol. 1998;5:836–9.

  17. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000:13;470-511.

  18. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody- mediated neuronal cell signaling in Sydenham chorea. Nat Med. 2003;9:914-20.

  19. Kirvan CA, Swedo SE, Kurahara D, Cunningham MW. Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham’s chorea. Autoimmunity. 2006;39:21-9.

  20. Gilbert DL. Acute and chronic chorea in childhood. Semin Pediatr Neurol. 2009;16:71-6.

  21. Martino D, Giovannoni G. Antibasal ganglia antibodies and their relevance to movement disorders. Curr Opin Neurol. 2004;17:425-32.

  22. Zhang D, Patel A, Zhu Y, Siegel A, Zalcman SS. Anti-streptococcus IgM antibodies induce repetitive stereotyped movements: Cell activation and co-localization with Fcα/μ receptors in the striatum and motor cortex. Brain Behav Immun. 2012;26:521-33.

  23. Kirvan CA, Swedo SE, Snider LA, Cunningham MW. Antibody-mediated neuronal cell signaling in behavior and movement disorders. J Neuroimmunol. 2006;179:173-9.

  24. Church AJ, Cardoso F, Dale RC, Lees AJ, Thompson EJ, Giovannoni G. Anti-basal ganglia antibodies in acute and persistent Sydenham’s chorea. Neurology. 2002;59:227-31.)

  25. Kirvan CA, Cox CJ, Swedo SE, Cunningham MW. Tubulin is a neuronal target of autoantibodies in Sydenham’s chorea. J Immunol. 2007;178:7412-21.

  26. Cox CJ, Sharma M, Leckman JF, Zuccolo J, Zuccolo A, Kovoor A, et al. Brain human monoclonal autoantibody from Sydenham chorea targets dopaminergic neurons in transgenic mice and signals dopamine D2 receptor: implications in human disease. J Immunol. 2013;191: 5524-41.

  27. Cunningham MW, Cox CJ. Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: a review of Sydenham chorea and beyond. Acta Physiol. (Oxf) 2016;216:90- 100.

  28. Ben-Pazi H, Stoner JA, Cunningham MW. Dopamine receptor autoantibodies correlate with symptoms in Sydenham’s chorea. PLoS One. 2013;8:e73516

  29. Hachiya Y, Miyata R, Tanuma N, Hongou K, Tanaka K, Shimoda K, et al. Autoimmune neurological disorders associated with group-A beta-hemolytic streptococcal infection. Brain Dev. 2013;35:670- 4.

  30. Williams KA, Swedo SE. Post-infectious autoimmune disorders: Sydenham’s chorea, PANDAS and beyond. Brain Res. 2015;1617:144-54.

  31. Mohammad SS, Ramanathan S, Brilot F, Dale RC. Autoantibody-associated movement disorders. Neuropediatrics. 2013;44:336-45

  32. Walker RH. Chorea. Continuum. (Minneap Minn) 2013;19:1242-63.

  33. Cardoso F, Seppi K, Mair KJ, Wenning GK, Poewe W. Seminar on choreas. Lancet Neurol. 2006;5:589-602.

  34. Cardoso F, Eduardo C, Silva AP, Mota CC. Chorea in fifty consecutive patients with rheumatic fever. Mov Disord. 1997;12:701–3.

  35. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009;8:844-56.

  36. Attoni T, Beato R, Pinto S, Cardoso F. Abnormal eye movements in three types of chorea. Arq Neuropsiquiatr. 2016;74:761-6.

  37. Gordon N. Sydenham’s chorea, and its complications affecting the nervous system. Brain Dev. 2009;31:11-4.

  38. Harsányi E, Moreira J, Kummer A, Meira ZMA, Cardoso F, Teixeira AL. Language Impairment in adolescents with Sydenham chorea. Pediatr Neurol. 2015;53:412-6.

  39. de Teixeira AL, Cardoso F, Maia DP, et al. Frequency and significance of vocalizations in Sydenham’s chorea. Parkinsonism Relat Disord. 2009;15:62-3.

  40. Maia DP, Fonseca PG, Camargos ST, Pfannes C, Cunningham MC, Cardoso F. Pregnancy in patients with Sydenham’s Chorea. Parkinsonism Relat Disord. 2012;18:458-61.

  41. Cardoso F, Vargas AP, Oliveira LD et al. Persistent Sydenham’s chorea. Mov Disord. 1999;14:805–7.

  42. Asbahr FR, Negrão AB, Gentil V, Zanetta DM, da Paz JA, Marques-Dias MJ, et al. Obsessivecompulsive and related symptoms in children and adolescents with rheumatic fever with and without chorea: a prospective 6-month study. Am J Psychiatry. 1998;155:1122-4.

  43. Punukollu M, Mushet N, Linney M, Hennessy C, Morton M. Neuropsychiatric manifestations of Sydenham’s chorea: a systematic review. Dev Med Child Neurol. 2016;58:16-28.

  44. Maia DP, Teixeira AL Jr, Quintão Cunningham MC, Cardoso F. Obsessive compulsive behavior, hyperactivity, and attention deficit disorder in Sydenham chorea. Neurology. 2005;64:1799-801.

  45. Gewitz MH, Baltimore RS, Tani LY, Sable CA, Carapetis J, Remeneyi B, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015;131:1806-18.

  46. Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet. 2012;379:953– 64.

  47. Bakdash T Goetz CG, Singer HS, Cardoso F. A child with recurrent episodes of involuntary movements. Mov Disord. 1999;14:146-54.

  48. Cardenas JF, Chapman K. Sydenham’s chorea as a presentation of moyamoya disease. Semin Pediatr Neurol. 2010;17:30-4.

  49. Ekici A, Yakut A, Yimenicioglu S, Carman KB, Saylısoy S. Clinical and neuroimaging findings of Sydenham’s chorea. Iran J Pediatr. 2014;24:300-6.

  50. Aron AM. Sydenham’s chorea: positron emission tomographic (PET) scan studies. J Child Neurol. 2005;20:832–3.

  51. Barsottini OG, Ferraz HB, Seviliano MM, Barbieri A. Brain SPECT imaging in Sydenham’s chorea. Braz J Med Biol Res. 2002;35:421-6.

  52. Beato R, Siqueira CF, Marroni BJ, Boanova LG, de Lima CF, Maia DP, et al. Brain SPECT in Sydenham’s chorea in remission. Mov Disord. 2014;29:256-8

  53. Dean SL, Singer HS. Treatment of Sydenham’s Chorea: A Review of the Current Evidence. Tremor Other Hyperkinet Mov. (N Y) 2017;7:456.

  54. Daoud AS, Zaki M, Shakir R, al-Saleh Q. Effectiveness of sodium valproate in the treatment of Sydenham’s chorea. Neurology. 1990;40:1140-1.

  55. Dhanaraj M, Radhakrishnan AR, Srinivas K, Sayeed ZA. Sodium valproate in Sydenham’s chorea. Neurology. 1985;35:114-5.

  56. Genel F, Arslanoglu S, Uran N, Saylan B. Sydenham’s chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens. Brain Dev. 2002;24:73–6.

  57. Teixeira AL, Cardoso F, Maia DP, Cunningham MC. Sydenham’s chorea may be a risk factor for drug induced parkinsonism. J Neurol Neurosurg Psychiatry. 2003;74:1350–1.

  58. Paz JA, Silva CA, Marques-Dias MJ. Randomized double-blind study with prednisone in Sydenham’s chorea. Pediatr Neurol. 2006;34:264–9.

  59. Barash J, Margalith D, Matitiau A. Corticosteroid treatment in patients with Sydenham’s chorea. Pediatr Neurol. 2005;32:205-7.

  60. van Immerzeel TD, van Gilst RM, Hartwig NG. Beneficial use of immunoglobulins in the treatment of Sydenham chorea. Eur J Pediatr. 2010;169:1151-4.

  61. Gwathmey K, Balogun RA, Burns T. Neurologic indications for therapeutic plasma exchange: 2013 update. J Clin Apheresis. 2014;29:211-9.

  62. Garvey MA, Snider LA, Leitman SF, Werden R, Swedo SE. Treatment of Sydenham’s chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol. 2005;20:424-9.

  63. World Health Organization, Rheumatic fever and rheumatic heart disease. Who technical report series 923. (Accessed January 1, 2017, at whqlibdoc.who.int/trs/WHO_TRS_ 923.pdf).

  64. Tumas V, Caldas CT, Santos AC, Nobre A, Fernandes RMF. Sydenham’s chorea: Clinical observations from a Brazilian movement disorder clinic. Parkinsonism Relat Disord. 2007;13:276-83.

  65. Gurkas E, Karalok ZS, Taskin BD, Aydogmus U, Guven A, Degerliyurt A, et al. Predictors of recurrence in Sydenham’s chorea: Clinical observation from a single center. Brain Dev. 2016;38:827- 34.

  66. Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry. 1998;155:264-71.

  67. Orefici G, Cardona F, Cox CJ, Cunningham MW. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). In: Ferretti JJ, Stevens DL, Fischetti VA, eds. Streptococcus pyogenes: basic biology to clinical manifestations. Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2016.




2020     |     www.medigraphic.com